Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. The obesity data keeps coming this week. We’ll get straight into it.
the need-to-know this morning
- Resolution said its experimental drug failed to reduce episodes of low blood sugar in patients with congenital hyperinsulinism, missing the efficacy goal of a Phase 3 trial.
- AC Immune said its immunotherapy showed the potential to slow the progression of parkinson’s disease, based on preliminary results from a mid-stage study.
- Rhythm Pharma announced positive results from a Phase 3 trial of setmelanotide in patients with obesity caused by POMC, PCSK1, or LEPR gene deficiencies.